GENOVESE, CAMILLA
GENOVESE, CAMILLA
Universita' degli Studi di MILANO
Epidemiology and Clinical Insights of Catheter-Related Candidemia in Non-ICU Patients with Vascular Access Devices
2024 G. Scaglione, M. Colaneri, M. Offer, L. Galli, F. Borgonovo, C. Genovese, R. Fattore, M. Schiavini, A. Taino, M. Calloni, F. Casella, A. Gidaro, F. Fassio, V. Breschi, J. Leoni, C. Cogliati, A. Gori, A. Foschi
Optimizing antibiotic therapy for intravenous drug users: a narrative review unraveling pharmacokinetics/pharmacodynamics challenges
2024 M. Colaneri, C. Genovese, P. Valsecchi, M. Calia, D. Cattaneo, A. Gori, R. Bruno, E. Seminari
Response to the Letter to the Editor Regarding “Prognostic Significance of NLR and PLR in COVID-19: A Multi-Cohort Validation Study”
2024 M. Canuti, F. Fassio, C. Genovese, A. Giacomelli, A.L. Ridolfo, E. Asperges, G. Albi, R. Bruno, S. Antinori, A. Muscatello, B. Mariani, C. Canetta, F. Blasi, A. Bandera, A. Gori, M. Colaneri
Proactive therapeutic monitoring of dalbavancin concentrations in the long-term management of chronic osteoarticular/periprosthetic joint infections
2024 D. Cattaneo, M. Fusi, L. Galli, C. Genovese, R. Giorgi, M. Matone, S. Merli, M. Colaneri, A. Gori
Carbapenem or new β-lactam-β-lactamase inhibitors? An Italian survey supported by SITA, SIMIT and SIAARTI to identify the factors affecting empiric antimicrobial therapy choice in real-life clinical practice
2024 M. Colaneri, C. Genovese, A. Lombardi, D. Holmes, A. Bandera, A. Gori
Prognostic Significance of NLR and PLR in COVID-19: A Multi-Cohort Validation Study
2024 M. Colaneri, C. Genovese, F. Fassio, M. Canuti, A. Giacomelli, A.L. Ridolfo, E. Asperges, G. Albi, R. Bruno, S. Antinori, A. Muscatello, B. Mariani, C. Canetta, F. Blasi, A. Bandera, A. Gori
Understanding the burden of antibiotic resistance: a decade of carbapenem-resistant Gram-negative bacterial infections in Italian intensive care units
2024 G. Scaglione, M. Perego, M. Colaneri, C. Genovese, F. Brivio, A. Covizzi, B. Viaggi, A. Bandera, A. Gori, S. Finazzi, E. Palomba
Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment With Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients
2023 A. Lombardi, G. Viero, S. Villa, S. Biscarini, E. Palomba, C. Azzara', N. Iannotti, B. Mariani, C. Genovese, M. Tomasello, A. Tonizzo, M. Fava, A. Grazia Valzano, L. Morlacchi, M. Francesca Donato, G. Castellano, R. Cassin, M. Carrabba, A. Muscatello, A. Gori, A. Bandera
Mortality of Patients With Candidemia and COVID-19: A Systematic Review With Meta-analysis
2023 M. Colaneri, E.M. Giusti, C. Genovese, L. Galli, A. Lombardi, A. Gori
Schistosomiasis in non-endemic areas: Italian consensus recommendations for screening, diagnosis and management by the Italian Society of Tropical Medicine and Global Health (SIMET), endorsed by the Committee for the Study of Parasitology of the Italian Association of Clinical Microbiologists (CoSP-AMCLI), the Italian Society of Parasitology (SoIPa), the Italian Society of Gastroenterology and Digestive Endoscopy (SIGE), the Italian Society of Gynaecology and Obstetrics (SIGO), the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV), the Italian Society of General Medicine and Primary Care (SIMG), the Italian Society of Infectious and Tropical Diseases (SIMIT), the Italian Society of Pediatrics (SIP), the Italian Society of Paediatric Infectious Diseases (SITIP), the Italian Society of Urology (SIU)
2023 A. Comelli, C. Genovese, F. Gobbi, G. Brindicci, S. Capone, A. Corpolongo, V. Crosato, V.D. Mangano, R. Marrone, M. Merelli, M. Prato, C.R. Santoro, S. Scarso, E. Vanino, V. Marchese, S. Antinori, C. Mastroianni, A. Raglio, F. Bruschi, A. Minervini, D. Dona, S. Garazzino, L. Galli, A. Lo Vecchio, A. Galli, G. Dragoni, C. Cricelli, N. Colacurci, E. Ferrazzi, A. Pieralli, A. Montresor, J. Richter, G. Calleri, A. Bartoloni, L. Zammarchi
Drug resistant tuberculosis in Italy through a global health lens
2023 F. Fama, C. Genovese, M. Raviglione, A. Gori
Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience
2023 D. Cattaneo, M. Fusi, M. Colaneri, C. Fusetti, C. Genovese, R. Giorgi, M. Matone, S. Merli, F. Petri, A. Gori
Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients
2023 A. Lombardi, G. Viero, S. Villa, S. Biscarini, E. Palomba, C. Azzarà, N. Iannotti, B. Mariani, C. Genovese, M. Tomasello, A. Tonizzo, M. Fava, A. Grazia Valzano, L.C. Morlacchi, M. Francesca Donato, G. Castellano, R. Cassin, M. Carrabba, A. Muscatello, A. Gori, A. Bandera
Safety Profile and Outcomes of Early COVID-19 Treatments in Immunocompromised Patients: A Single-Centre Cohort Study
2022 S. Biscarini, S. Villa, C. Genovese, M. Tomasello, A. Tonizzo, M. Fava, N. Iannotti, M.M. Bolis, B. Mariani, A. Grazia Valzano, L.C. Morlacchi, F. Donato, G. Castellano, R. Cassin, M.D.R. Carrabba, A. Muscatello, A. Gori, A. Bandera, A. Lombardi
What is the impact of SARS-CoV-2 pandemic on antimicrobial stewardship programs (ASPs)? The results of a survey among a regional network of infectious disease centres
2022 A. Comelli, C. Genovese, A. Lombardi, C. Bobbio, L. Scudeller, U. Restelli, A. Muscatello, S. Antinori, P. Bonfanti, S. Casari, A. Castagna, F. Castelli, A.D. Monforte, F. Franzetti, P. Grossi, M. Lupi, P. Morelli, S. Piconi, M. Puoti, L. Pusterla, A. Regazzetti, M. Rizzi, S. Rusconi, V. Zuccaro, A. Gori, A. Bandera
COVID-19 vaccines: Evidence, challenges and the future
2021 E. Tanzi, C. Genovese, M. Tettamanzi, C. Fappani, M.C. Raviglione, A. Amendola